<DOC>
	<DOC>NCT00383227</DOC>
	<brief_summary>Comparison of adjuvanted hepatitis B vaccine to double dose of Engerix™-B in pre- /haemodialysis patients aged ≥15 years</brief_summary>
	<brief_title>Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female &gt; = 15 years of age at the time of the first vaccination. Written informed consent obtained from the subject/ from the parents or guardians of the subject. Seronegative for antiHBs antibodies, antiHBc antibodies &amp; Hepatitis B Surface antigen (HBsAg). If the subject was a female, she was of nonchildbearing potential or, if of childbearing potential, she had to be abstinent or use adequate contraceptive precautions for one month prior to enrollment and up to two months after the last vaccination. Prehaemodialysis patient* or a patient on haemodialysis. Use of any investigational or nonregistered drug or vaccine other than the study vaccine during the study period or within 30 days preceding the first dose of study vaccine. Previous vaccination against hepatitis B. History of hepatitis B infection. Known exposure to hepatitis B virus within 6 weeks. Pregnant or lactating female Clinically abnormal ALT/AST values (&gt; 3 times normal values)</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>